Glycodendrimers as new tools in the search for effective anti-HIV DC-based immunotherapies

Dendritic cells (DC), which play a major role in development of cell-mediated immunity, represent opportunities to develop novel anti-HIV vaccines. Dendrimers have been proposed as new carriers to ameliorate DC antigen loading and in this way, we have determined the potential use of maltose decorated neutrally and positively charged G4 glycodendrimers. Thus, immunostimulatory properties of these glycodendrimers on human DC were evaluated in the context of HIV infection. We have demonstrated that DC treated with glycodendrimers were fully functional with respect to viability, maturation and HIV-derived antigens uptake. Nevertheless, iDC and mDC phenotypes as well as mDC functions such as migration ability and cytokines profile production were changed. Our results showed the potential carrier properties of glycodendrimers to activate the immune system by the way of DC stimulation. This is the first study for exploring the use of maltose-functionalized dendrimers-peptides complexes as a potential DC-based vaccine candidate.From the Clinical EditorIn this paper, maltose-functionalized dendrimer-peptide complexes are demonstrated to activate the immune system by way of dendritic cell (DC) stimulation. DC vaccination using this methodology may be applicable to a variety of conditions, including infections and potentially cancer.

Graphical AbstractMaltose decorated positively charged PPi dendrimers showed antigen carrier properties and were able to activate the immune system by the way of DC stimulation. Thus, glycodendrimers could be used as valid tools in the development of DC-based vaccine or adjuvant in anti-HIV vaccine development when associated with HIV-derived peptides. This is the first study for exploring the use of maltose-functionalized dendrimers-peptides complexes as a potential vaccine candidate.Figure optionsDownload high-quality image (153 K)Download as PowerPoint slide